The Chordopoxvirinae subfamily (Family
Poxviridae) includes human and animal pathogens with zoonotic potential. Among them are
viruses that are commonly used as viral and vaccination vectors, some of them bearing
oncolytic or oncotropic potential for anti-tumor therapy. The authors have developed a
versatile triplex real-time PCR assay that facilitates differentiation between the genera
(i) Orthopoxvirus, (ii) Avipoxvirus, and (iii) Parapoxvirus and Molluscipoxvirus.
Hydrolysis probes labelled with Yakima Yellow, Cy5, and FAM specifically bind to Ortho-,
Avi-, Para- or Molluscipoxviruses, respectively. The authors detected the expected four
poxvirus genera in purified DNA from 47 poxviral samples, whereas four samples belonging
to the genera Yatapoxvirus and Capripoxvirus were not detected. Taken together, a set of
24 negative controls comprising other viruses including non-target poxvirus-genera as well
as bacteria, yeast, mammal, and avian cells were tested to proof the specificity of the
assay. Probit analysis revealed a detection limit of three copies per reaction (95%
confidence level) for the Ortho-, Avi-, and Para-/Molluscipoxvirus-PCR using two
independent Cycler-Master mix combinations.
AlcockR, CottinghamMG. Long-term thermostabilization of live poxviral and adenoviral vaccine
vectors at supraphysiological temperatures in carbohydrate glass. Sci Transl Med., 2010; 2(19):19ra12.
AmannR, RohdeJ. A new rabies vaccine based on a recombinant ORF virus (parapoxvirus)
expressing the rabies virus glycoprotein. J Virol., 2013; 87(3):1618–30.
CottinghamMG, AndersenRF. Recombination-mediated genetic engineering of a bacterial artificial
chromosome clone of modified vaccinia virus Ankara (MVA). PLoS
One., 2008; 3(2):e1638.
9.
CottinghamMG, GilbertSC. Rapid generation of markerless recombinant MVA vaccines by en passant
recombineering of a self-excising bacterial artificial chromosome. J Virol Methods. 2010; 168(1–2):233–6.
10.
CottoneR, ButtnerM. Analysis of genomic rearrangement and subsequent gene deletion of the
attenuated Orf virus strain D1701. Virus Res., 1998; 56(1):53–67.
11.
DarlingAE, MauB. Progressive mauve: Multiple genome alignment with gene gain, loss and
rearrangement. PLoS One., 2010; 5(6):e11147.
12.
DomiA, MossB. Cloning the vaccinia virus genome as a bacterial artificial chromosome in
Escherichia coli and recovery of infectious virus in mammalian
cells. Proc Natl Acad Sci USA., 2002; 99(19):12415–20.
13.
DownieAW, EspanaC. Comparison of Tanapox virus and Yaba-like viruses causing epidemic
disease in monkeys. J Hyg (Lond). 1972; 70(1):23–32.
14.
DownieAW, Taylor-RobinsonCH. Tanapox: A new disease caused by a pox virus. Br
Med J., 1971; 1(5745):363–8.
15.
EssbauerS, PfefferM. Zoonotic poxviruses. Vet Microbiol. 2010; 140(3–4):229–36.
16.
European Parliament. 2000/54/EC. Official J Eur Union. 2000; 43(L
019):69–70.
17.
FennerF. The global eradication of smallpox. Med J
Aust., 1980; 1(10):455.
18.
GuoZS, McCartJA. Vaccinia viral vectors for vaccines and oncolytic
virotherapy. In: GuoZS, editor. Gene and cell therapy, 4th ed.. Boca Raton, FL: CRC Press; 2015. p. 133–56.
19.
HallTA. BioEdit: A user-friendly biological sequence alignment editor and
analysis program for Windows 95/98/NT. Nucl Acids Symp
Ser., 1999; 41(1):95–8.
20.
HolmesP, RicheyM. Zoonotic transmission of bovine papular stomatitis virus. Vet Rec., 2011; 169(9):235–6.
21.
IbrahimMS, AntwerpenM. Complete genome sequence of the Embu virus strain
SPAn880. Genome Announc. 2014; 2(6):e01155–14.
22.
IsaacsSN. Working safely with vaccinia virus: Laboratory technique and review of
published cases of accidental laboratory infections. In: IsaacsSN, editor. Vaccinia virus and poxvirology. New
York: Humana Press; 2012. 890: P. 1–22.
23.
JourdierTM, MosteC. Local immunotherapy of spontaneous feline fibrosarcomas using recombinant
poxviruses expressing interleukin 2 (IL2). Gene Ther., 2003; 10(26):2126–32.
24.
Koppers-LalicD, HoebenRC. Non-human viruses developed as therapeutic agent for use in
humans. Rev Med Virol., 2011; 21(4):227–39.
25.
LaroccaC, SchlomJ. Viral vector-based therapeutic cancer vaccines. Cancer J., 2011; 17(5):359–71.
National Center for Biotechnology
Information. Database resources of the National Center for
Biotechnology Information. Nucleic Acids Res., 2015; 43(Database issue): D6–D17.
28.
NitscheA, PauliG. Sporadic human cases of cowpox in Germany. Euro
Surveill. 2007; 12(4):E070419 070413.
29.
OsadebeLU, ManthiramK. Novel poxvirus infection in 2 patients from the United
States. Clin Infect Dis., 2015; 60(2):195–202.
30.
PruittK, BrownG. The reference sequence (RefSeq) database. 2002 Oct 9 [Updated 2012 Apr
6]. In: McEntyreJ, OstellJ, editors. The NCBI handbook [Internet]. Bethesda,
MD: National Center for Biotechnology
Information; 2002. Chapter 18. Available from: www.ncbi.nlm.nih.gov/books/NBK21091/.
31.
RohdeJ, AmannR. New Orf virus (Parapoxvirus) recombinant expressing H5 hemagglutinin
protects mice against H5N1 and H1N1 influenza A virus. PLoS
One., 2013; 8(12):e83802.
32.
ShchelkunovSN. An increasing danger of zoonotic orthopoxvirus
infections. PLoS Pathog. 2013; 9(12):e1003756.
33.
ShchelkunovSN, TotmeninAV. Alastrim smallpox variola minor virus genome DNA
sequences. Virology. 2000; 266(2):361–86.
34.
ShchelkunovSN, TotmeninAV. Analysis of the monkeypox virus genome. Virology. 2002; 297(2):172–94.
35.
StellbergerT, HaaseM. Characterization of recombinant vaccinia viruses by MLPA
technology. Appl Biosafety. 2014; 19(3):132–40.
36.
StichA, MeyerH. Tanapox: First report in a European traveller and identification by
PCR. Trans R Soc Trop Med Hyg., 2002; 96(2):178–9.
37.
VacchelliE, EggermontA. Trial watch: Oncolytic viruses for cancer therapy. Oncoimmunology. 2013; 2(6):e24612.
